Hyperargininemia
📧 Sign up to get email alerts when something new happens for Hyperargininemia.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2025-12-09EMA Authorised: Loargys (Pegzilarginase) — Immedica Pharma AB
The EMA has authorized Loargys (pegzilarginase) by Immedica Pharma AB for hyperargininemia, with orphan medicine designation indicating a ra…
-
CLINICAL_TRIALS research · 2025-04-17Clinical Trial Update: Liver Disease in Urea Cycle Disorders
A clinical trial update indicating ongoing recruitment for a study on liver disease in patients with urea cycle disorders, including OTC def…
-
CLINICAL_TRIALS trial_result · 2024-11-19Clinical Trial Update: Efficacy and Safety of Pegzilarginase in Patients With Arginase 1 Deficiency [Phase 3]
Phase 3 results evaluating Pegzilarginase for Arginase I Deficiency (hyperargininemia) have been posted after completion of the study, detai…
-
CLINICAL_TRIALS trial_result · 2023-07-27Clinical Trial Update: A Study of Safety of Weekly Subcutaneous Pegzilarginase in Subjects With Arginase 1 Deficiency [Phase 3]
Phase 3 trial evaluating safety of weekly subcutaneous pegzilarginase in arginase 1 deficiency has been terminated.
-
CLINICAL_TRIALS trial_result · 2023-07-27Clinical Trial Update: A Study of AEB1102 (Pegzilarginase) in Patients With Arginase I Deficiency [Phase 2]
Phase 2 trial update of AEB1102 (pegzilarginase) in patients with Arginase I deficiency completed.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2019-06-12Clinical Trial Update: A Phase 1/2 Study of AEB1102 in Patients With Arginase I Deficiency [Phase 1, Phase 2]
Phase 1/2 clinical trial of AEB1102 in Arginase I deficiency/hyperargininemia completed.